Biogenvs.Regeneron
BIIB vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.3× larger than Biogen by market cap; Regeneron trades at the lower P/E (17.6 vs 39.4); year to date, Biogen leads (+24.1% vs −4.2%).
Side by side
| BIIB | REGN | |
|---|---|---|
| Market cap | $32.9B | $76.1B |
| Price | $225.71 | $746.54 |
| Today | +3.3% | +0.9% |
| Return YTD | +24.1% | −4.2% |
| Return 1Y | +44.7% | +31.2% |
| Since June 26, 2026 | +4.5% | +18.0% |
| P/E | 39.4 | 17.6 |
| P/S | 3.3 | 4.9 |
| P/B | 1.7 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More BIIB & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.